<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39314902</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2515-1355</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Therapeutic advances in vaccines and immunotherapy</Title><ISOAbbreviation>Ther Adv Vaccines Immunother</ISOAbbreviation></Journal><ArticleTitle>Comparative 60-day effectiveness of bivalent versus monovalent mRNA vaccines in Shelby County: a population-level analysis.</ArticleTitle><Pagination><StartPage>25151355241278852</StartPage><MedlinePgn>25151355241278852</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25151355241278852</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/25151355241278852</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Two monovalent mRNA vaccines, available in December 2020, were demonstrated to have high efficacy against both the original SARS-CoV-2 strain and variants circulating through the summer and into the fall of 2021. In the context of the Omicron/BA.1 variant, which was predominant from late fall 2021 into winter of 2022 in the United States, and subsequent Omicron subvariants that have been predominant thereafter, vaccine effectiveness of the monovalent mRNA vaccine option is attenuated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">We aim to investigate the relative effectiveness of the bivalent booster compared to the monovalent booster against SARS-CoV-2 infection in the 60 days following administration in Shelby County, TN.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">This observational population-based cohort study utilizes COVID-19 surveillance data to identify adults who were vaccinated with a monovalent booster dose between August 1, 2022 and August 30, 2022 or a bivalent booster dose between September 1, 2022 and September 30, 2022. Both groups were followed for COVID-19 status for 60 days from their administration date.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We calculated incidence rates with 95% confidence intervals and propensity-adjusted hazard ratios with 95% confidence intervals of COVID-19 diagnosis in the 60 days following administration of the booster dose between the bivalent group and the monovalent group. Stratified analysis was conducted by age group (18-34, 35-64, and 65+ years old).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The incidence of reported SARS-CoV-2 infection was substantially higher for those who received the monovalent booster, across age groups. Overall, we observed a 51% lower hazard of infection during the study period among those who received the bivalent booster, compared to the monovalent booster.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These results support and extend prior findings that the bivalent booster dose may be more effective in preventing infection against the Omicron sub-variants of SARS-CoV-2.</AbstractText><CopyrightInformation>© The Author(s), 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plaxco</LastName><ForeName>Allison P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0001-8179-2537</Identifier><AffiliationInfo><Affiliation>Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, 214 Robison Hall, 3825 Desoto Ave, Memphis, TN 38152, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bureau of Epidemiology, Preparedness, and Informatics, Shelby County Health Department, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kmet</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bureau of Epidemiology, Preparedness, and Informatics, Shelby County Health Department, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeltzer</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bureau of Epidemiology, Preparedness, and Informatics, Shelby County Health Department, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Vikki G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Vaccines Immunother</MedlineTA><NlmUniqueID>101718382</NlmUniqueID><ISSNLinking>2515-1355</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron Variant</Keyword><Keyword MajorTopicYN="N">bivalent</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39314902</ArticleId><ArticleId IdType="pmc">PMC11418355</ArticleId><ArticleId IdType="doi">10.1177/25151355241278852</ArticleId><ArticleId IdType="pii">10.1177_25151355241278852</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384(5): 403–416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreño JM, Alshammary H, Tcheou J, et al.. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 2021; 602: 682–688.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016197</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi EK, Britton A, Fleming-Dutra KE, et al.. Association between 3 doses of mRNA COVID-19 Vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. January 2022; 327(7): 639–651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaxco AP, Kmet JM, Nolan VG, et al.. Association between mRNA vaccination and infection from SARS-CoV-2 during the Delta and Omicron BA.1 Waves: a population-level analysis. AJPM Focus 2023; 2(4): 100150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10630621</ArticleId><ArticleId IdType="pubmed">37941824</ArticleId></ArticleIdList></Reference><Reference><Citation>
Coronavirus (COVID-19)
Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. Fda.gov, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use (2022, accessed October 1, 2022).</Citation></Reference><Reference><Citation>
Possible Side Effects. Cdc.gov. Updated September 14, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html?s_cid=10509:covid%20vaccine%20reactions:sem.ga:p:RG:GM:gen:PTN:FY21 (accessed 18 October 2022).</Citation></Reference><Reference><Citation>Chalkias S, Harper C, Vrbicky K, et al.. A bivalent omicron-containing booster Vaccine against Covid-19. N Engl J Med. 2022; 387: 1279–1291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al.. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection – increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep 71(48): 1526–1530</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9721148</ArticleId><ArticleId IdType="pubmed">36454688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Xu Y, Gu Y, et al.. Effectiveness of bivalent boosters against severe Omicron infection. N Engl J Med. 2023;388(8):764–766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933929</ArticleId><ArticleId IdType="pubmed">36734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Auvigne V, Tamandjou Tchuem CR, Schaeffer J, et al.. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines – a matched cohort study in France. Vaccine 2023; 41(38): 5490–5493.</Citation><ArticleIdList><ArticleId IdType="pubmed">37541823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim RK, Choe YJ, Jang EJ, et al.. Comparative effectiveness of COVID-19 bivalent versus monovalent mRNA vaccines in the early stage of bivalent vaccination in Korea: October 2022 to January 2023. J Korean Med Sci 2023; 38(46): e396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681846</ArticleId><ArticleId IdType="pubmed">38013649</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae C, Kim RK, Jang EJ, et al.. Comparing the effectiveness of bivalent and monovalent COVID-19 vaccines against COVID-19 infection during the winter season of 2022-2023: A real-world retrospective observational matched cohort study in the Republic of Korea. Int J Infect Dis 2023; 135: 95–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">37572956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Kang L, Guo Z, et al.. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open 2022; 5(8): e2228008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396366</ArticleId><ArticleId IdType="pubmed">35994285</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention, COVID-19 Response. United States COVID-19 Community Levels by County (version date: Jan 09, 2023). https://data.cdc.gov/Public-Health-Surveillance/United-States-COVID-19-Community-Levels-by-County/3nnm-4jni</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al..; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61(4): 344–349. PMID: 18313558</Citation><ArticleIdList><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal R, Buchan SA, Nguyen L, et al.. Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against omicron severe outcomes among adults aged ⩾50 Years in Ontario, Canada: a Canadian Immunization Research Network Study. J Infect Dis. 2024; 229(2): 394–397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873169</ArticleId><ArticleId IdType="pubmed">37798119</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>